Cost-effectiveness of treating schizophrenia with ziprasidone versus other antipsychotics considering adverse drug reactions and non-compliance;Die effizienz der behandlung der schizophrenie mit ziprasidon im vergleich zu anderen neuroleptika unter berücksichtigung von arzneimittelnebenwirkungen und noncompliance

Gesundheitsokonomie und Qualitatsmanagement

Volumn 10, Issue 2, 2005, Pages 96-101

  Volz, H P ^a   Sadre Chirazi Stark, M ^b   Resch, Ansgar ^c  

^a Schloss Werneck ^*  (Germany)

^b Abt Psychiat und Psychotherapie   (Germany)

^c PFIZER INC   (United States)

Author keywords

Cost effectiveness analysis; Schizophrenia; Ziprasidone

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ARTICLE; BODY WEIGHT DISORDER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; PATIENT COMPLIANCE; PROBABILITY; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 17644391120     PISSN: 14322625     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-857951     Document Type: Article

References (33)

1. Torrey EF. Prevalence studies in schizophrenia. Br J Psychiatry 1987; 150: 598-60
2. Carpenter WT Jr, Buchanan RW. Schizophrenia. N Engl J Med 1994; 330: 681-690
3. Salize HJ. Die Kosten der Schizophrenie - was wissen wir (nicht)? Psych Prax 2001; 28 (1): 21-28
4. Schnabel R, Clouth J. Kosten der Frühverrentung am Beispiel der Schizophrenie. Gesök 2002; 7: 381-388
5. Deister A. Schizophrenie und verwandte Psychosen. Stuttgart: Wiss. Verl.-Ges., 1998
6. Kissling W, Hoffler J, Seemann U et al. Direkte und indirekte Kosten der Schizophrenie. Fortschr Neurol Psychiatr 1999; 67 (1): 29-36
7. Stern MP, Williams K, Haffner MS. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002; 136 (8): 575-581
8. Allison DB, Mentore JL, Moonseong H et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psych 1999; 156: 1686-1696
9. Weiden PJ, Iqbal N, Mendelowitz AJ et al. Best clinical practice with ziprasidone: update after one year of experience. J Psych Prac 2002; 8 (2): 81-97
10. Tandon R, Jubson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocinology 2003; 28 (Suppl 1): 9-26
11. Leucht S, Barnes TRE, Kissling W et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
12. Sorensen SV, Russel JM, Mackell JA. An economic comparison of anti-psychotics in treatment of schizophrenia. ISPOR 8th Annual International Meeting; Arlington, Mai 2003: 18-21
13. Einheitlicher Bewertungsmaßstab (EBM); Stand: Oktober 2001; Dienstauflage der Kassenärztlichen Bundesvereinigung
14. Punktwert aufgrundlage von eigenen Berechnungen, basierend auf den Angaben von 19 Kassenärztlichen Vereinigungen für das Quartal II/III 2003
15. Verband der privaten Krankenversicherung e.V. (Hrsg). PKV-Zahlen-bericht 2001/2002
16. MediMedia. Gelbe Liste Pharmindex Preisvergleich 2004, www.gelbeliste.de
17. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-429
18. Gilbert PL, Harris MJ, McAdams LA et al. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psych 1995; 52; 173-187
19. Csernansky JG, Mahmoud R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346 (1): 16-22
20. Deckert C, Höffler J, Kortmann J et al. Kostenanalyse der Schizophrenie-Behandlung in Deutschland. Gesök 2001; 6: 161-166
21. von der Schulenburg JM, Uber A, Höffler J et al. Untersuchung zu den I direkten und indirekten Kosten der Schizophrenie. Gesök 1998; 3: 81-87
22. Almond S, O'Donnel O. Cost Analysis of the treatment of schizophrenia in the UK. Pharmecon 1998; 13: 575-588
23. Launois R, von der Schulenburg M, Knapp M et al. Cost-effectiveness of sertindole vs olanzapine or haloperidol: a comprehensive model. Int J Psych Clin Prac 1998; 2 (2): 79-86
24. Lecomte P, de Hert M, van Dijk M et al. A1-year cost-effectiveness model for the treatment of chronic schizophrenia in acute exacerbation in Belgium. Val Health 2000; 3(1): 1-11
25. Guest JF, Cookson RF. Cost of schizophrenia to UK society. Pharmecon 1999; 15 (6): 597-610
26. Tran PV, Hamilton SH et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychiatry 1997; 17 (5): 407-418
27. Tran PV, Dellva MA et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58 (5): 205-211
28. Addington D, Pantelis C, Dineen M et al. Ziprasidone vs Risperidone in Schizophrenia: 52 Weeks' Comparative Data. APA, 2003
29. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizo-affective disorder. Am J Psychiatry 2001; 158 (5): 765-774
30. Simpson GM, Glick ID, Weiden PJ et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 1837-1847
31. Keck P, Buffenstein A, Ferguson J et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173-184
32. Daniel DG, Zimbroff DL, Potkin SG et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder, a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491-505
33. Van Putten T et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190